ABSTRACT
Heart failure (HF) is a progressive syndrome that appears as the final phase of most cardiac diseases and is manifested as a decreased contractile function. Contraction in cardiomyocytes arises by the Ca 2+ induced Ca 2+ release mechanism, where Ca 2+ entry (I Ca ) through Ca 2+ channels (DHPRs) activates Ca 2+ release channels (RyRs) in the junctional sarcoplasmic reticulum (SR). This is the base of cardiac excitation-contraction (EC) coupling. To elucidate the mechanisms underlying depressed function of the failing heart, analysis of EC coupling main elements have been undertaken. I Ca density is usually maintained in HF. However, failing myocytes show a reduced SR Ca 2+ release. Then, if the trigger of SR Ca 2+ release is maintained, why is SR Ca 2+ release depressed in HF? Analyses of the DHPR-RyR coupling efficiency have revealed a decrease in the I Ca efficacy to trigger Ca 2+ release in failing myocytes. In terminal heart failure without hypertrophy, a decrease in SR Ca 2+ load can account for the decreased SR Ca 2+ release. Fewer Ca 2+ sparks (elementary units of SR Ca 2+ release) are triggered by an equivalent I Ca in hypertrophied failing myocytes, suggesting a functional or spatial reorganization of the space T-tubule junctionnal SR. This theory is supported by new data showing that the T-tubule density is reduced in failing cells.
INTRODUCTION
The heart adapts to work in different situations to ensure adequate blood distribution. This adaptation can be fast, in response to an acute need, i.e. in a stress situation, adrenergic stimulation will have a fast inotropic effect. In response to a sustained pathological stimulus, the heart adapts to adjust cardiac output. In this case, the heart experiments biochemical, electrophysiological and structural changes, globally known as "remodeling" (1) , that usually involve hypertrophy. Although hypertrophy is initially beneficial, sustained cardiac hypertrophy is a ] i activating neighboring ryanodine receptors, RyRs.
leading predictor for the development of sudden death and heart failure (HF) (2, 3) .
For a long time, the process of heart remodeling has been divided in three phases (4) . After the first phase ("development", hours to days after the initiating stimuli) the heart hypertrophies to meet the body needs. This period is called "compensated" hypertrophy. The compensation provided by hypertrophy is often limited and the cardiac pump function is compromised. During this new situation of "decompensated" hypertrophy, HF develops. The failing heart function is depressed and has less capacity to respond to acute needs. In systolic HF, the failing muscle pumps out blood with less strength than normal. In diastolic HF, the pump function may be normal, but it cannot relax normally and refilling of the ventricles is impaired. This last situation is characteristic of the HF found in the elderly.
Because Ca 2+ activates contraction in the cardiac muscle, the major mechanism underlying contractile alterations during cardiac remodeling and its final outcome, heart failure, could be alterations in the Ca 2+ signaling, or in the contractile proteins itself. We will focus here in collected data regarding Ca 2+ signaling in heart remodeling.
Etiology and stage of disease do matter
HF is a progressive syndrome that appears as the final phase of most cardiac diseases. The initiating insult can be acute as in myocardial infarction, or gradual as in hemodynamic load (pressure or volume overload) or as in the case of many hereditary cardiomyopathies. Other acquired diseases, such as viral myocarditis can also induce heart remodeling. One must take into consideration the above discussion when integrating data regarding Ca 2+ handling collected in different experimental models of hypertrophy and HF and define precisely the stage of the disease. Many apparent contradictory data may just reflect the different stages in the disease progression. Ideally the best tissues to analyze would be human tissues. However, one major difficulty resides in the access to normal hearts, which is highly limited for obvious reasons (5, 6) . Only terminally failing hearts obtained from transplants are available. Regardless of the variability in etiology, age and gender, all failing tissues are obtained from patients with long-term medications, which clearly hampers analysis and proper understanding of the disease progression. Consequently, many animal models have been used in an attempt to overcome these problems and better standardize the experimental conditions. The etiology and stage of the pathology can be determined more accurately, and the effect of medication is avoided although one cannot always extrapolate from the many animal models to human heart. Moreover, no animal model reproduces the wide variety of causes and manifestations of clinical syndromes in human. In addition to these limitations, several variables reviewed recently (7) underlie discrepancies found in different animal models: (i) pathophysiology of myocardial failure which varies among models; (ii) the studied molecular level, since discrepancies can potentially exist between mRNA level, protein level and function, both in normal and diseased tissues (differences in terms of protein isoforms, sub-unit assembly, mRNA or protein degradation, regulation); (iii) the stage of the disease and time of measurement; and (iv) the experimental conditions themselves which are a major variable among groups.
Ca 2+ HANDLING IN THE NORMAL HEART
Contraction arises when intracellular free Ca 2+ level increases following activation by an action potential. Figure 1 ] i , taking place in the restricted space between L-type Ca 2+ channels and RyRs (9) . The common pool theory would result in an all-or-none response, while a graded response is expected to result from the local control of EC coupling theory; the latter being physiologically more relevant. This theory was supported by the finding of non-propagating localized elevations of [Ca 2+ ] i that correspond to the opening of one or few RyRs, named Ca 2+ sparks (10) ( Figure 1C ] i transient decay phase is perhaps the most consistent alteration (15) (16) (17) (18) . It has been correlated with a decrease in SERCA activity or expression, which is observed in some cases. However, it seems that contraction kinetics and [Ca 2+ ] i transient characteristics are not constant in failing human ventricular cells, depending on dilated or ischemic cardiomyopathy etiology (19). These differences may account for the divergence in findings regarding SERCA in failing human myocytes that has been shown to be decreased or unaltered (for review see (20)). These alterations probably become critical at high beating rates because SR Ca 2+ accumulation during shorter diastolic period may become dramatically inadequate to provide sufficient Ca 2+ during systole. This process contributes largely to the negative force-frequency relationship reported in the failing human heart (21-23). Interestingly, after enhancing SERCA activity by either knocking out phospholamban or overexpressing SERCA, HF is prevented or rescued, respectively (24) (25) (26) (27) ] i transient amplitude seems modified in the remodeled heart, although different models have provided conflicting data. An increase of the SR Ca 2+ release has been reported in models of early cardiac hypertrophy, together with hyperactivity, in spontaneous hypertensive rats (29) (30) (31) . The increase in SR Ca 2+ release during early stages of hypertrophy development has been correlated with longer AP duration (32) while SR Ca 2+ load is maintained (31) . Some other models of hypertrophy have shown normal [Ca 2+ ] i transient amplitude (33, 34) , that can be reduced under some challenges, such as increase (35) homeostasis. There is indeed general agreement that disturbed SR function plays a significant role in the altered systolic and diastolic performance in human as well as in various animal models (48) . To determine the defect(s) underlying the failure, investigators have long analyzed each of the elements involved in EC coupling. Here, we will overview these elements both in human and animal models of HF, focusing particularly on I Ca and SR Ca 2+ release. Simultaneous measurements of both I Ca and SR Ca 2+ release provide valuable information on the effectiveness of EC coupling. (56) have confirmed the increase in NCX exchanger expression in a mice hypertrophy model but paradoxically the NCX current, I NCX , was decreased. However, most investigators have found an increase in I NCX both in hypertrophied and failing hearts (57) (58) (59) (60) . From an electrophysiological point of view, the increase in I NCX may be arrhythmogenic (61) ; however, it is not clear whether the increase in NCX function is adaptive or deleterious for the Ca 2+ handling of the hypertrophied and failing cell. In fact, because the NCX can work in both directions, it may be involved both in contraction and in relaxation (28). It seems that the increase in NCX function would be compensatory in cell relaxation. In human failing hearts with normal diastolic function, the NCX was upregulated while in hearts with impaired diastolic function the NCX expression was normal (62) . Regarding the systolic function, a compensatory role has been proposed in compensatory hypertrophy, but the issue is more complicated. The underlying mechanism of the increased contraction would be an increase in SR Ca 2+ load, favored by the reverse mode of the up regulated NCX (59) . However in HF, up-regulation of the NCX could be deleterious because, working in forward mode would tend to decrease SR Ca 2+ content (63) . In summary, there is strong evidence that the NCX is up regulated both in hypertrophy and HF, but the physiopathologic consequences are unclear (64).
Triggers of SR

Ca 2+ channels
Ca 2+ channels open transiently in response to depolarization and serve as the major pathway for Ca 2+ entry into the myocytes. They permeate Ca 2+ driven by its electrochemical gradient in a time-and voltage-dependent manner. In the myocardium, the coexistence of at least two populations of voltage-dependent Ca 2+ channels (L-type and T-type) is well established. The T-type Ca 2+ current (I Ca,T ) has not been found in all mammalian species investigated, including human, but in the species where it is present, the efficacy of I Ca,T to trigger SR Ca 2+ release is much weaker than that of the L-type I Ca (65) .
The L-type Ca 2+ channels (DHPRs) have been linked to the plateau phase of the action potential and play a crucial role in EC coupling. Initially termed 'slow inward current' (66, 67) , I Ca activates at depolarizations positive to -40 mV, peaks near 0 mV and declines gradually at more positive voltages. Decay kinetics of the current include a fast Ca 2+ -dependent component and a slow voltagesensitive component. At the single channel level, this channel occupies three different basic modes: no opening or mode 0, short opening or mode 1 and long opening or mode 2 (68) . The DHPR is constituted by a pore-forming subunit ( α1c subunit), associated with auxiliary transmembrane subunits (α2-δ subunit) and cytoplasmic regulatory subunits (β subunit) (69) .
Many studies of I Ca in hypertrophy and HF have been conducted but the results remain ambiguous (reviewed in (6, (70) (71) (72) (73) ). When investigating Ca 2+ entry via I Ca at least two parameters should be examined: (i) peak amplitude because it grades Ca 2+ release from the SR; and, (ii) the decay kinetics because inactivation, which terminates Ca 2+ entry, is likely to influence the AP repolarization. Regarding I Ca density, the general trend is that cardiac hypertrophy ranges from no change to significant increase, whereas HF ranges from no change to significant decrease. It was thus tentatively proposed that I Ca density would increase at early stages, be normalized during compensated hypertrophy, to finally decrease in late stage failure (70) . This hypothesis was first postulated by Scamps et al. (74) to reconcile the unmodified I Ca density observed in hypertrophied myocytes with the increase shown in hypertensive non-hypertrophied myocytes (75) . This hypothesis predicts a decrease of I Ca in severe HF such as human samples (always at the end-stage). However, in most studies of human failing myocytes and in animal models, the density of I Ca is unchanged (6).
Both amplitude and kinetics of I Ca may in part contribute to AP shape (76) . Even if I Ca peak density is maintained, slowing of its inactivation has been described in HF (reviewed in (73) ) that might contribute to AP prolongation. Increased net Ca 2+ entry would consequentially tend to enhance SR Ca 2+ load and increase contraction.
Whole-cell current depends on both, number and individual properties of functional channels. Therefore, even if the macroscopic current seems unchanged, any modification of individual channel activity may be important in cardiac hypertrophy and HF. In human HF, Ca 2+ channels were shown to switch activity from mode 1 to mode 2, showing higher availability and open probability (77) . Since only one study analyzed single channel properties during human HF, one cannot definitively conclude whether this reflects a general feature. Moreover, extrapolation to whole-cell currents is difficult. In particular, one would expect larger I Ca in HF cells. Surprisingly, the same study showed unchanged whole-cell I Ca . One possibility to reconcile this disparity would be that HF cells have fewer but more active Ca 2+ channels (78) as a result of an increase in channel phosphorylation. The latter could underlie the mode switching, too (79) .
In this regard, myocytes from failing hearts are less responsive to β-adrenergic stimulation, which may be due to β-adrenergic receptor down-regulation or desensitization (80) . Another possibility is that the level of Ca 2+ channel phosphorylation is increased in failing myocytes. Several facts support this interpretation: (1) the adrenergic tone is increased in HF patients (81) (2) singlechannel records show increased activity (77), (3) some other proteins show increased phosphorylation state (82) , and (4) β-adrenergic receptor blockers help in HF therapy (83) . Furthermore, strengthening the β-adrenergic system has been proved beneficial to prevent the development of HF in transgenic mice, even in the presence of the instigating cause (45) (84). However, there is so far not enough evidence that Ca 2+ channels are phosphorylated in human HF. In fact, forskolin, which also activates PKA phosphorylation of Ca 2+ channels but bypasses β-adrenergic receptors, can increase I Ca similarly in failing and control cells (85) .
At the molecular level, a large discrepancy has been, once again, reported. In human HF (86) was revealed that mRNA expression for the α1c-subunit and the abundance of dihydropyridine binding sites were reduced. More recently, unchanged expression of α1c-subunits was reported in end-stage or diastolic HF (77, (87) (88) (89) . Ancillary subunits play important functional roles in the formation and stabilization of L-type Ca 2+ channels (69, 90). Although mRNA levels of the α2/δ-subunit remained unchanged in diastolic human HF (87), either reduced or unchanged β-subunit mRNA levels were reported in human HF (77, 87) . Nevertheless, the ratio of β-subunit mRNA over α1c-subunit mRNA was significantly reduced in both studies. Moreover, cardiac myocytes contain several isoforms of the α1c-subunit. Hypertrophy after myocardial infarction in rats is associated with re-emergence of the fetal isoform of the α1c gene (91) . Similarly, the relative abundance of isoforms is changed in human ischemic HF (88) , although the functional significance of isoform switching has not been established yet.
Regardless of the potential changes of I Ca during cardiac hypertrophy and failure, two points that are usually underestimated have to be considered: (1) the electrophysiological landmark of hypertrophy and HF is the prolongation of AP duration induced, at least in part, by the down-regulation of the transient outward K + current (73, (92) (93) (94) that regulates the height of the AP plateau during which I Ca is active. Prolonged depolarization during the extended AP will thus enhance I Ca contribution (95-97); (2) assuming unaltered I Ca density in hypertrophy implies that the magnitude of I Ca (and by extension, the total number of functional channels) is significantly increased in parallel with enlargement of cardiac myocytes. Therefore, a decrease in I Ca density or DHPRs means a down-or noregulation, whereas unchanged or increased I Ca density means up-regulation. Interestingly, recent studies on a transgenic mouse model indicate that cardiac-specific overexpression of the L-type Ca 2+ channel induces the development of hypertrophy and sets the stage for lateonset HF (98).
Activity of RyRs
Biochemical analysis of human failing hearts has revealed that the RyRs are hyperphosphorylated (82) (detailed in other chapter of this issue), although no difference has been reported in RyR phosphorylation in the fast-paced dog HF model (99) . Bilayer experiments have shown that RyRs phosphorylation would increase its open probability and accelerate adaptation (100 
Effectiveness of coupling
Even if I Ca density is maintained, the AP duration is increased in cardiac hypertrophy and HF (38, 73, 102 (38) . The first was the Dahl rat model. These animals are a strain of Sprague-Dawley that was selected by its sensitivity to sodium intake. The salt-sensitive rats develop hypertension when fed with a high salt diet. With time, their hearts hypertrophy and ultimately develop HF. The salt-resistant rats do not develop any alteration at the same high salt diet (104) . At the time of experiments, the saltsensitive animals experienced cardiac hypertrophy although no signs yet of congestive HF. However, isolated myocytes were failing. They showed a normal I Ca (although slowed inactivation kinetics, see later) but the associated [Ca 2+ ] i transient and contraction (shortening) was weak (38) . To analyze the reason why the SR Ca 2+ release was reduced, one approach was to estimate the SR Ca 2+ load that was shown to be unchanged. Next was to count and analyze the Ca 2+ sparks evoked by I Ca at several potentials. Such analysis showed that the number of Ca 2+ sparks triggered by equivalent I Ca was greatly reduced in failing myocytes compared to match controls (38) . That is, the coupling between L-type Ca 2+ channels and RyRs was defective. Nevertheless, the cells maintained the ability to compensate by β-adrenergic stimulation. These results were compared with another model of pressure-overload disease in overt HF. Similar data was obtained, although in this case the β-adrenergic stimulation was ineffective to overcome the spark is produced by a group of RyRs acting in concert. Analysis of RyRs showed that the density of RyRs was unchanged in these failing myocytes, as was their Ca 2+ sensitivity (38) . This is further supported by the unchanged characteristics of Ca 2+ sparks. The later finding suggests that there is no change in the activity of RyRs and confirms that the SR Ca 2+ load is unchanged in these models of HF. In fact, once the RyR opens, Ca 2+ is released down its concentration gradient. If the SR load were reduced, the Ca 2+ spark amplitude would be reduced because it depends on SR Ca 2+ load (106) . Because RyRs were found normal in number and Ca 2+ sensitivity, it seems that there are fewer Ca 2+ sparks in failing myocytes because the release units failed to be triggered. Since the trigger (I Ca ) is normal, these data suggest that the relationship DHPRs -RyRs is altered in HF. Few other studies have analyzed the elementary EC coupling in other models of HF. Recently we have shown that the same defect is also present in a model of HF after myocardial infarct in the rat (46) . In the calsequestrin overexpression transgenic mice, the number of Ca 2+ sparks was also shown to be reduced even though the SR Ca 2+ load was highly increased (42) . But in this case, the fewer Ca 2+ sparks could be due to the reduced RyR density of this transgenic model. During compensated hypertrophy, in the spontaneously hypertensive rats, bigger Ca 2+ sparks underlie bigger [Ca 2+ ] i transients and enhanced contractility, while the triggering I Ca was also unchanged (31) . Taken together, these data provide evidence that the relationship between DHPR and RyRs is modulated during the development of cardiac hypertrophy with: (i) an increase in the EC coupling gain underlying the increased contractility of this adaptive process; and (ii) a decrease as HF develops, underlying the decreased contractility.
Defects underlying the EC uncoupling
Data from human HF cells have been collected from terminally failing hearts obtained during transplantation. Very often, different etiologies are mixed together and the patients have a long history of medication, which render conclusions difficult. Nevertheless, it is always useful and necessary to know what happens in the human heart; even if limited to the end-stage of HF. Ventricular myocytes isolated from terminally failing human hearts had a decreased EC coupling gain (37 ] i transient was thus due to a smaller SR Ca 2+ release (39) although in these non-hypertrophied failing cells, a decrease in SR Ca 2+ content may, at least in part, explain the decrease in the efficacy of the I Ca to trigger SR Ca 2+ release (107) . Similar explanation has been suggested in a model of paced-induced HF (41) . Interestingly, this model also induces HF without cellular hypertrophy (60) .
In cardiac hypertrophy and HF with cellular hypertrophy, the reorganization of the cellular structure as cell grows may be important determinants of defective EC coupling. In fact, there is a growing body of evidence suggesting that alterations in cardiac cytoskeletal proteins may induce dilated cardiomyopathy (108) . Moreover, several transgenic mice with alterations in the cytoskeleton develop HF, such us the muscle LIM protein (MLP) knock out mice. They develop dilated cardiomyopathy and HF with hypertrophy (109) and decrease in the EC coupling efficiency (45) . MLP is a protein involved in cytoarchitecture organization. Likewise, desmin (constituent of the intermediate filaments in muscle) deficiency induces cardiomyopathy (110) with cell hypertrophy and alterations in Ca 2+ handling (111) . Interestingly, acquired cardiac hypertrophy induces changes in the cytoskeleton. More precisely, it has been reported that HF following chronic hypertension is associated with an increase in the density of another cytoskeleton component, the microtubules (112). Very interestingly, microtubule proliferation in the failing cell may be involved in the contractile abnormalities since microtubule depolymerization normalizes contraction in failing cells (112). Moreover, it has been shown that microtubule proliferation can decrease [Ca 2+ ] i transient (113) , whereas microtubule depolymerization increases [Ca 2+ ] i transient (114) and modifies Ca 2+ sparks characteristics (115) . Because CICR occurs mainly at the region of junctional SR (where RyRs are located) close to the TT (where the DHPRs are located), a rearrangement in the spatial organization of DHPRs and RyRs in the dyadic cleft or a disruption in the TT system during remodeling would have severe consequences in EC coupling in the failing myocytes (Figure 2 ). In this line, alterations in the TT system have been reported in hypertrophied cells from human failing myocardium (116) . In a HF model of paced dog with significant cellular hypertrophy, a decrease in TT density has been shown (78) , and it seems that a similar pattern could be present in human HF (117). ] i transient at high frequencies in rat ventricular myocytes (122). Moreover, thapsigargin and ryanodine induced similar "pharmacological" I Ca facilitation (119, 122) . In this regard, I Ca facilitation in HF can be used as an index of the coupling DHPR-RyR. Interestingly, I Ca facilitation is rarely observed in human HF when comparing either with ventricular cells from other mammals or atrial cells from HF and non-HF patients (72, 119, 123, 124) . Furthermore, even at low stimulation rates, inactivation of I Ca is slow in HF cells which is consistent with weaker SR Ca 2+ -release and, thereby, weaker Ca 2+ -dependent inactivation (119).
Feed-back RyR-DHPR
PERSPECTIVES: IMPORTANCE OF Ca
2+
CYCLING IN THE PROGRESSION OF HF
Remodeling during cardiac hypertrophy and failure is usually accompanied by complex changes in gene expression reprogramming (1) . In recent years, it has become apparent that Ca 2+ also plays a role in this longerterm regulation. This represents a second mechanism, via long-term adaptation, by which Ca 2+ might alter the function of cardiac muscle. It has been suggested that alterations in Ca 2+ handling proteins progressively exacerbate a hypertrophic or cardiomyopathic phenotype, in part, through sustained activation of Ca 2+ -sensitive signaling pathways. The intricate signaling network that causes cardiac hypertrophy (125) involves Ca 2+ -dependent gene regulation as a necessary component (126, 127) . In the first phase of hypertrophy response (min to hours), early response genes, e.g. c-fos, c-myc, c-jun, are activated (128) . In cardiac myocytes, transcriptional induction via c-jun has been related to intracellular Ca 2+ (129, 130) . Moreover, Ca 2+ influx through L-type Ca 2+ channels is critical for early response gene stimulation by a variety of stimuli, including neurotransmitters and growth factors (131, 132) . Intracellular [Ca 2+ ] may also affect expression of late genes. Subject of intense research over the past decade, the signaling cascades underlying alteration in gene expression in cardiac hypertrophy and HF converge on the MAPK cascade (133, 134) . Activation of this pathway by hypertrophy stimulus depends on transsarcolemmal influx of Ca 2+ (135) . A Ca 2+ sensitive mechanism, which involves Ca 2+ /Calmodulin pathway, seems to be important for activation of MAPK cascade (136) . Over-expression of calmodulin (CaM) in transgenic mice causes myocytes hypertrophy (137) . Calmodulin, when activated by Ca 2+ , modulates the activity of a number of enzymes, including CaM-dependent protein kinases involved in transcriptional regulation (47, 138, 139) . Recently, it has been shown that the CaM kinase pathway is sufficient to activate many features of cardiac hypertrophy and failure in vivo (140, 141) . Recent studies have shown that the Ca 2+ /calcineurin pathway is a necessary component for the expression of hypertrophy markers (126) although this has been subject of controversy (142) . As matter of fact, overexpressing calcineurin in a transgenic mouse produced a rapid development of hypertrophy and HF (143) . Calcineurin is a specific Ca 2+ -dependent phosphatase that dephosphorylates transcription factors, which turn on a panel of hypertrophy genes.
Thus, when considering all the published studies on HF, a central and perhaps essential role for intracellular Ca 2+ is inescapable, not only on altered cardiac contraction, but also on altered gene expression. In cardiomyocytes, EC coupling thus regulates the transcription activity by process termed excitation-transcription coupling. This process represents an elementary pathway whereby, through Ca 2+ signaling, the electrical activity of a cell feeds back upon and shapes the cellular genetic program (144, 145) . This has been nicely evidenced in smooth muscle (146, 147) . For instance, activation of Ca 2+ influx through the L-type Ca 2+ channel by membrane depolarization increased Ca 2+ sparks frequency, which in turn activated the cAMP-responsive element-binding protein and subsequent c-fos expression.
Recently, we provided new data on the implication of this pathway in an aldosterone-induced down-regulation of the transient outward K + current (I to,1 ) functional expression, which might be involved in hypertrophy and HF (148) . This mineralocorticoid hormone might be one of the primary factors in the remodeling of hypertrophy and HF (149) (150) (151) . Incubation of adult rat isolated cardiomyocytes in the presence of aldosterone induces a specific and genomic up-regulation of functional expression of L-type Ca 2+ channels (152). When this stimulation is sufficient, then it induces an increase in Ca 2+ sparks occurrence, which is able to down-regulate the functional expression of I to1 (148) .
We should expect, in the near future, new insights into the mechanisms by which intracellular Ca 2+ influences the progression of hypertrophy and HF.
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